Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

Nonalcoholic Steatohepatitis Clinical Trial

Official title:

A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP0678 and the Effect of Food on ZSP0678 Pharmacokinetics in Chinese Healthy Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04137055
• Other study ID #: ZSP0678-19-01
• Status: Completed
• Phase: Phase 1
• Start date: November 19, 2019
• Est. completion date: December 9, 2020

Study information

• Verified date: July 2021
• Source: Guangdong Raynovent Biotech Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single-and multiple-oral doses of ZSP0678 on fasted condition, and characterize PK of ZSP0678 on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts (Ascending single dose, multiple dose and food effect). Participants will receive either ZSP0678 or placebo .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 104
• Est. completion date: December 9, 2020
• Est. primary completion date: December 9, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Subjects are required to meet the following criteria in order to be included in the trial:

1. Signature signed informed consent before the trial, and fully understood the content, process and possible adverse reactions.

2. Subjects must be willing and able to complete the research according to the experimental protocol.

3. Subjects (including partners) are willing to take effective contraceptive measures and have no pregnancy plan during the whole study period until 6 months after drug withdrawal.

4. Male and female subjects aged 18-50 (including 18 and 50)

5. Body weight of male subjects should not be less than 50kg and that of female subjects should not be less than 45kg.Body mass index (BMI) = weight (kg)/height 2 (m2), the range of 19~26kg/m2 (including the critical value);

6. Physical condition:No significant abnormalities in medical history, including cardiovascular system, liver, kidneys, gastrointestinal system, neural system, respiratory system (eg.asthma,asthma induced by exercise,chronic obstructive pulmonary disease), mental, metabolism, etc.

7. Subjects in general good health or No significant abnormalities in the opinion of the investigator as determined by vital signs and a physical examination.

Exclusion Criteria:

• Eligible subjects must not meet any of the following exclusion criteria:

1. Allergic constitution (allergic to many drugs, especially to ingredients similar to the test drug and food)

2. The average daily smoking are more than 5 cigarettes within 3 months prior to screening.

3. Known history of drug or alcohol abuse.(defined as consumption of more than 30g of ethanol a day for male and more than 20 g for female )

4. Subjects who donated blood or bleeding profusely(> 400 mL)in the 3 months preceding study screening.

5. History of dysphagia or any gastrointestinal illness that affects drug absorption, including a history of frequent nausea or vomiting from any cause, irregular gastrointestinal motility, such as habitual diarrhea, constipation, or irritable bowel syndrome.

6. History or presence of any disease or condition known to increase the risk of bleeding, eg.acute gastritis, duodenal ulcer, etc.

7. Participated in another clinical research study and received any investigational products within 3 months prior to dosing.

8. Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal within 14 days prior to screening.

9. History of having any special food(including dragon fruit, mango, grapefruit, etc.),strenuous exercises,or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 14 days prior to screening.

10. Subjects who cannot tolerate standard meals (this clause only applies to subjects participating in food impact studies).

11. Presence of clinically significant abnormalities in ECG or QTcB>450ms in males,or QTcB>470ms in females.

12. Pregnancy or breastfeeding at screening and during the study.All female subjects of childbearing potential must have a negative urine pregnancy test at screening and during the trial.

13. Any clinically significant abnormality upon physical examination or in the clinical laboratory tests. History or presence of a clinically significant gastrointestinal, renal, hepatic, neurologic, hematic, endocrine, neoplastic, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular disorder(s) (but not limited to above disorders).

14. Presence of human immunodeficiency virus (HIV), viral hepatitis(including hepatitis C virus (HCV) or hepatitis B virus (HBV) ),treponema pallidum antibodies at screening.

15. Any acute illness or concomitant medication from screening to first dosing.

16. Have chocolate, any food or beverage that contains caffeine ,xanthine and alcohol within 24 hours prior to dosing.

17. Positive for urine drug screening or history of substance abuse for a period of 5 consecutive years before screening.

18. As judged by the researcher, it is not suitable to join the clinical researcher.

Related Conditions & MeSH terms

• Fatty Liver
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Intervention

Drug:
• ZSP0678-10mg
ZSP0678 tablet administered orally under fasted condition
• ZSP0678-30mg
ZSP0678 tablets administered orally under fasted condition
• ZSP0678-60mg
ZSP0678 tablets administered orally under fasted condition
• ZSP0678-120mg
ZSP0678 tablets administered orally under fasted condition
• ZSP0678-180mg
ZSP0678 tablets administered orally under fasted condition
• ZSP0678-240mg
ZSP0678 tablets administered orally under fasted condition
• ZSP0678-320mg
ZSP0678 tablets administered orally under fasted condition
• ZSP0678
ZSP0678 tablets administered orally under fasted or fed condition
• ZSP0678-Dose 1
ZSP0678 tablets administered orally once daily for 14 Days
• ZSP0678-Dose 2
ZSP0678 tablets administered orally once daily for 14 Days
• ZSP0678-Dose 3
ZSP0678 tablets administered orally once daily for 14 Days
• ZSP0678 Placebo
Participants will receive placebo matching to ZSP0678 orally.

Locations

Country	Name	City	State
China	Beijing Friendship Hospital Affiliated to Capital Medical Universit	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Guangdong Raynovent Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and severity of adverse events (AEs) and Serious Adverse Events(SAE) following oral doses of ZSP0678 and placebo.		SAD Group: Up to 5 days, MAD: Up to 18 days, FE group: Up to11 days after first dose ]
Primary	Tmax	The time after dosing when Cmax occurs	UP to 5, 18, 11 days for SAD, MAD, FE part respectively
Primary	Cmax	Maximum concentration	UP to 5, 18, 11 days for SAD, MAD, FE part respectively
Primary	t1/2	t1/2 is defined as the time to decline half of the drug concentration in plasma.	UP to 5, 18, 11 days for SAD, MAD, FE part respectively
Primary	AUCinf(AUC0-8)	Area under the curve extrapolated until time is infinity (AUCinf)	UP to 5, 18, 11 days for SAD, MAD, FE part respectively
Primary	AUClast(AUC0-t)	AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.	UP to 5, 18, 11 days for SAD, MAD, FE part respectively
Primary	CL/F	CL/F is defined as the ratio of total clearance(Cl) to bioavailability(F).	UP to 5, 18, 11 days for SAD, MAD, FE part respectively
Primary	?z	?z is defined as the ratio between the elimination of compound per unit time and the total amount of compound.	UP to 5, 18, 11 days for SAD, MAD, FE part respectively
Primary	CLr	CLr is defined as how many milliliters of plasma in which some substance can be completely eliminated in the unit time (per minute) of two kidneys.	UP to 5, 18, 11 days for SAD, MAD, FE part respectively
Primary	Multiple-dose plasma PK parameter: Rac of ZSP0678 at steady state	Rac (Accumulation Index) is defined as the ratio between AUC0-XX in Day XX and AUC0-XX in Day1	UP to 18 days.
Primary	Multiple-dose plasma PK parameter: DF of ZSP0678 at steady state	DF is defined as the percentage of fluctuation in steady state is 100 * (Cmax, ss - Cmin, ss)/Cavg, ss.	UP to 18 days.
Primary	Multiple-dose plasma PK parameter: Cmin of ZSP0678 at steady state	Cmin is defined as the minimum observed concentration of drug in plasma at steady state.	UP to 18 days.